216 related articles for article (PubMed ID: 26229437)
1. Escherichia coli Nissle 1917 bacterial ghosts retain crucial surface properties and express chlamydial antigen: an imaging study of a delivery system for the ocular surface.
Montanaro J; Inic-Kanada A; Ladurner A; Stein E; Belij S; Bintner N; Schlacher S; Schuerer N; Mayr UB; Lubitz W; Leisch N; Barisani-Asenbauer T
Drug Des Devel Ther; 2015; 9():3741-54. PubMed ID: 26229437
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo uptake study of Escherichia coli Nissle 1917 bacterial ghosts: cell-based delivery system to target ocular surface diseases.
Stein E; Inic-Kanada A; Belij S; Montanaro J; Bintner N; Schlacher S; Mayr UB; Lubitz W; Stojanovic M; Najdenski H; Barisani-Asenbauer T
Invest Ophthalmol Vis Sci; 2013 Sep; 54(9):6326-33. PubMed ID: 23920373
[TBL] [Abstract][Full Text] [Related]
3. Bacterial Ghosts as antigen and drug delivery system for ocular surface diseases: Effective internalization of Bacterial Ghosts by human conjunctival epithelial cells.
Kudela P; Koller VJ; Mayr UB; Nepp J; Lubitz W; Barisani-Asenbauer T
J Biotechnol; 2011 May; 153(3-4):167-75. PubMed ID: 21501636
[TBL] [Abstract][Full Text] [Related]
4. Delivery of a Chlamydial Adhesin N-PmpC Subunit Vaccine to the Ocular Mucosa Using Particulate Carriers.
Inic-Kanada A; Stojanovic M; Schlacher S; Stein E; Belij-Rammerstorfer S; Marinkovic E; Lukic I; Montanaro J; Schuerer N; Bintner N; Kovacevic-Jovanovic V; Krnjaja O; Mayr UB; Lubitz W; Barisani-Asenbauer T
PLoS One; 2015; 10(12):e0144380. PubMed ID: 26656797
[TBL] [Abstract][Full Text] [Related]
5. Split immune response after oral vaccination of mice with recombinant Escherichia coli Nissle 1917 expressing fimbrial adhesin K88.
Remer KA; Bartrow M; Roeger B; Moll H; Sonnenborn U; Oelschlaeger TA
Int J Med Microbiol; 2009 Nov; 299(7):467-78. PubMed ID: 19467927
[TBL] [Abstract][Full Text] [Related]
6. The effect of probiotic Escherichia coli strain Nissle 1917 lipopolysaccharide on the 5-aminosalicylic acid transepithelial transport across Caco-2 cell monolayers.
Stětinová V; Smetanová L; Kholová D; Květina J; Svoboda Z; Zídek Z; Tlaskalová-Hogenová H
Gen Physiol Biophys; 2013 Sep; 32(3):371-80. PubMed ID: 23846256
[TBL] [Abstract][Full Text] [Related]
7. Enhanced anti-proliferative efficacy of epothilone B loaded with Escherichia coli Nissle 1917 bacterial ghosts on the HeLa cells by mitochondrial pathway of apoptosis.
Zhu W; Hao L; Liu X; Borrás-Hidalgo O; Zhang Y
Drug Dev Ind Pharm; 2018 Aug; 44(8):1328-1335. PubMed ID: 29521115
[TBL] [Abstract][Full Text] [Related]
8. Antigen discovery and delivery of subunit vaccines by nonliving bacterial ghost vectors.
Walcher P; Mayr UB; Azimpour-Tabrizi C; Eko FO; Jechlinger W; Mayrhofer P; Alefantis T; Mujer CV; DelVecchio VG; Lubitz W
Expert Rev Vaccines; 2004 Dec; 3(6):681-91. PubMed ID: 15606353
[TBL] [Abstract][Full Text] [Related]
9. Escherichia coli Nissle 1917 ghosts alleviate inflammatory bowel disease in zebrafish.
Chen H; Lei P; Ji H; Ma J; Fang Y; Yu H; Du J; Qu L; Yang Q; Luo L; Zhang K; Wu W; Jin L; Sun D
Life Sci; 2023 Sep; 329():121956. PubMed ID: 37473802
[TBL] [Abstract][Full Text] [Related]
10. Antagonistic effects of probiotic Escherichia coli Nissle 1917 on EHEC strains of serotype O104:H4 and O157:H7.
Rund SA; Rohde H; Sonnenborn U; Oelschlaeger TA
Int J Med Microbiol; 2013 Jan; 303(1):1-8. PubMed ID: 23312798
[TBL] [Abstract][Full Text] [Related]
11. Construction and In Vitro Evaluation of a Tumor Acidic pH-Targeting Drug Delivery System Based on
Ma Y; Liu Q; Hu A; Jiang S; Wang S; Liu R; Han K; Wang J
Bioengineering (Basel); 2022 Sep; 9(9):. PubMed ID: 36134979
[TBL] [Abstract][Full Text] [Related]
12. Bacterial navigation for tumor targeting and photothermally-triggered bacterial ghost transformation for spatiotemporal drug release.
Xie S; Zhang P; Zhang Z; Liu Y; Chen M; Li S; Li X
Acta Biomater; 2021 Sep; 131():172-184. PubMed ID: 34171461
[TBL] [Abstract][Full Text] [Related]
13. Genetic engineering of probiotic Escherichia coli Nissle 1917 for clinical application.
Ou B; Yang Y; Tham WL; Chen L; Guo J; Zhu G
Appl Microbiol Biotechnol; 2016 Oct; 100(20):8693-9. PubMed ID: 27640192
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair.
Zyrek AA; Cichon C; Helms S; Enders C; Sonnenborn U; Schmidt MA
Cell Microbiol; 2007 Mar; 9(3):804-16. PubMed ID: 17087734
[TBL] [Abstract][Full Text] [Related]
15. Green fluorescent protein for detection of the probiotic microorganism Escherichia coli strain Nissle 1917 (EcN) in vivo.
Schultz M; Watzl S; Oelschlaeger TA; Rath HC; Göttl C; Lehn N; Schölmerich J; Linde HJ
J Microbiol Methods; 2005 Jun; 61(3):389-98. PubMed ID: 15767015
[TBL] [Abstract][Full Text] [Related]
16. Probiotic Escherichia coli Nissle 1917 reduces growth, Shiga toxin expression, release and thus cytotoxicity of enterohemorrhagic Escherichia coli.
Mohsin M; Guenther S; Schierack P; Tedin K; Wieler LH
Int J Med Microbiol; 2015 Jan; 305(1):20-6. PubMed ID: 25465158
[TBL] [Abstract][Full Text] [Related]
17. [Escherichia coli Nissle 1917 as safe vehicles for intestinal immune targeted therapy--a review].
Xia P; Zhu J; Zhu G
Wei Sheng Wu Xue Bao; 2013 Jun; 53(6):538-44. PubMed ID: 24028055
[TBL] [Abstract][Full Text] [Related]
18. Modulation of bacterial ghosts--induced nitric oxide production in macrophages by bacterial ghost-delivered resveratrol.
Koller VJ; Dirsch VM; Beres H; Donath O; Reznicek G; Lubitz W; Kudela P
FEBS J; 2013 Mar; 280(5):1214-25. PubMed ID: 23289719
[TBL] [Abstract][Full Text] [Related]
19. Advances in
Chen H; Lei P; Ji H; Yang Q; Peng B; Ma J; Fang Y; Qu L; Li H; Wu W; Jin L; Sun D
Mater Today Bio; 2023 Feb; 18():100543. PubMed ID: 36647536
[TBL] [Abstract][Full Text] [Related]
20. More than a marine propeller--the flagellum of the probiotic Escherichia coli strain Nissle 1917 is the major adhesin mediating binding to human mucus.
Troge A; Scheppach W; Schroeder BO; Rund SA; Heuner K; Wehkamp J; Stange EF; Oelschlaeger TA
Int J Med Microbiol; 2012 Dec; 302(7-8):304-14. PubMed ID: 23131416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
